Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
Ritsu SumiyoshiHaruko TashiroSumiko SaitoTakuji MatsuoTadashi YamamotoKensuke MatsumotoJun OoiNaoki ShirafujiPublished in: Medicine (2020)
GO monotherapy could be a conditioning regimen of 2nd allo HSCT from the same donor as the first HSCT for relapsed AML patients.
Keyphrases
- acute myeloid leukemia
- stem cell transplantation
- acute lymphoblastic leukemia
- high dose
- stem cells
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- hematopoietic stem cell
- ejection fraction
- low dose
- newly diagnosed
- hodgkin lymphoma
- diffuse large b cell lymphoma
- chronic kidney disease
- prognostic factors
- open label
- bone marrow
- case report
- clinical trial
- mesenchymal stem cells
- systemic lupus erythematosus